Target intelligence / Profile preview

Coronary atherosclerosis (CAD) (CAD)

Target
CAD
Molecular classification
Other
01

Overview

Coronary atherosclerosis is a chronic inflammatory disease of the coronary arteries characterized by the progressive accumulation of atheromatous plaques within the arterial walls [1, 2, 5]. The pathological process typically initiates with endothelial dysfunction and the subendothelial deposition of oxidized low-density lipoproteins (LDL), which trigger an immune response involving macrophage recruitment and foam cell formation [2, 7]. Over time, these deposits harden and narrow the arterial lumen, significantly restricting oxygen-rich blood flow to the heart muscle (myocardium) [1, 4]. In the clinical setting, coronary atherosclerosis manifests as stable or unstable angina and can progress to acute coronary syndrome if a plaque ruptures, causing sudden thrombotic occlusion [2, 4, 12]. Pharmacological management aims to reduce cardiovascular risk and stabilize existing plaques through the use of statins, antiplatelets, and antihypertensive agents [5, 11]. While many drugs treat the symptoms or risk factors of the disease by targeting specific enzymes or receptors, coronary atherosclerosis itself represents a broad disease state rather than a single molecular target [6, 10]. It remains the leading cause of morbidity and mortality worldwide, driving the need for novel therapies targeting vascular inflammation and lipid regulation [6, 10].

Other names
Coronary artery diseaseCoronary heart diseaseIschemic heart diseaseArteriosclerotic heart diseaseAtherosclerotic cardiovascular disease
02

Mechanism of action

Drugs used to manage coronary atherosclerosis act through multiple molecular mechanisms, including the inhibition of HMG-CoA reductase to lower systemic cholesterol, inhibition of cyclooxygenase-1 (COX-1) or P2Y12 receptors to prevent platelet aggregation, and blockade of beta-adrenergic receptors or angiotensin-converting enzyme (ACE) to reduce cardiac workload and manage blood pressure. Additionally, PCSK9 inhibitors enhance the recycling of LDL receptors to further clear cholesterol from the blood.

03

Biological functions

Inflammatory responseLipid metabolismVascular remodelingEndothelial dysfunctionAtherogenesis
04

Disease associations

Cardiovascular diseaseMyocardial infarctionHeart failureAngina pectorisChronic coronary syndrome
05

Safety considerations

Increased risk of major bleeding with dual antiplatelet therapyStatin-associated muscle symptoms and myopathyHypotension and electrolyte imbalances from antihypertensive agentsTherapeutic resistance in high-risk patientsPolypharmacy and patient non-adherence
06

Interacting drugs

Atorvastatin

8 more in the full profile.

07

Biomarkers

Low-density lipoprotein cholesterol (LDL-C)High-sensitivity C-reactive protein (hs-CRP)Cardiac troponin ICardiac troponin TApolipoprotein B (ApoB)Lipoprotein(a)

Beyond the preview

Go deeper on Coronary atherosclerosis (CAD) (CAD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coronary atherosclerosis (CAD) (CAD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call